---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-049850"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:45:45.290222+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics reports Q3 net loss $32.2M, raises $125M; cemsidomide 53% ORR at 100 µg

## Summary
- Revenue $11.2M, net loss $32.2M ($0.44 EPS) vs $15.4M revenue and $24.7M loss in Q3 2024.
- Completed equity offering of $125M gross proceeds in Oct 2025; potential additional $225M from warrants.
- Phase 1 cemsidomide data: 53% ORR at 100 µg dose; one patient achieved MRD-negative complete response.
- Entered clinical trial collaboration with Pfizer to evaluate cemsidomide + elranatamab; Pfizer supplies drug at no cost.
- Cash $199.8M as of Sep 30, excluding $125M raise; runway extended to end of 2028.

## SEC filing metadata
- accession: 0001628280-25-049850
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828025049850/0001628280-25-049850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828025049850/cccc-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-049850
- JSON: https://secwatch.observer/filing/0001628280-25-049850.json
- Plain text: https://secwatch.observer/filing/0001628280-25-049850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.